Letters and medicine recalls sent to healthcare professionals in January 2025
Source: gov.uk (2025-02-26)

A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.

Letters

In January 2025, the following letters were sent or provided to relevant healthcare professionals:
- Veoza▼ (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment (https://assets.publishing.service.gov.uk/media/67bde2e65d6b30e896ac6d35/Veoza_DHPC.pdf)
- Sodiofolin® (folinic acid) 50mg/ml solution for injection/infusion, strengths 100mg and 400mg, batches C240164A, C240218B and C240218C, PL 11587/0005 – requirement to use a PES or PVDF filter due to observation of particles and potential risk of thrombo-embolic event (https://assets.publishing.service.gov.uk/media/67bde372729cf14d438d76c3/Sodiofolin_DHPC.pdf)
- Dectova (zanamivir hydrate) solution for infusion 10mg/mL: Interim supply of EU shared pack stock to mitigate United Kingdom (UK) supply disruption (https://assets.publishing.service.gov.uk/media/67bde44f21d07694be8d76d6/Dectova_DHPC.pdf)
- Dectova (zanamivir hydrate) solution for infusion 10mg/mL: important information for healthcare professionals about the expiry date of certain batches (https://assets.publishing.service.gov.uk/media/67bde55289b4a58925ac6d36/Dectova_2_DHPC.pdf)
- Updated Imvanex suspension for injection - smallpox and mpox vaccine (live modified vaccinia virus ankara) modified vaccinia ankara - interim supply of EU stock to mitigate supply disruption (https://assets.publishing.service.gov.uk/media/67bde5ae44ceb49381213c7f/Imvanex_DHPC.pdf)
- Kineret® (anakinra) 100 mg solution for injection in a pre-filled syringe: interim supply of foreign packs to mitigate supply disruption of UK packs (PLGB 30941/0018) (https://assets.publishing.service.gov.uk/media/67bde61121d07694be8d76dd/Kineret_DHPC.pdf)
- Notification of Seroxat® (paroxetine hydrochloride) 10mg, 20mg and 30mg tablets discontinuation (https://assets.publishing.service.gov.uk/media/67bde6b1729cf14d438d76c8/Seroxat_DHPC.pdf)
Medicine Recalls and Notifications

In January 2025, recalls and notifications for medicines were issued on:

Class 2 Medicines Recall: Bristol Laboratories Limited, Amlodipine Bristol Lab 2.5 mg Tablets, EL (25)A/04 (https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bristol-laboratories-limited-amlodipine-bristol-lab-2-dot-5-mg-tablets-el-25-a-slash-04). Issued 30 January 2025. Bristol Laboratories Limited is recalling the batches specified in this notification as a precautionary measure due to possible microbial contamination.

UPDATE: Class 2 Medicines Recall: Tesco Health Dry Cough Relief 200ml, Asda Strong Dry Tickly Cough 200ml, Almus Dry Cough Relief & Bells Dual Action Dry Cough, EL(25)A/03 (https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-tesco-health-dry-cough-relief-200ml-asda-strong-dry-tickly-cough-200ml-almus-dry-cough-relief-and-bells-dual-action-dry-cough-el-25-a-slash-03). Issued 22 January 2025. Bells Healthcare is recalling the listed batches of dextromethorphan hydrobromide BP containing products as a precautionary measure, due to foreign material detected in some bottles.

Class 4 Medicines Notification: Irbesartan 150 mg and 300 mg film-coated tablets, EL(25)A/02 (https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-irbesartan-150-mg-and-300-mg-film-coated-tablets-el-25-a-slash-02). Issued 13 January 2025. Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.